Author

Christopher R. Denz

AstraZeneca (United States)ORCID 0000-0003-2296-8963Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Andrew KoffiD· 1 shared Anton Mikhailovich SafonoviD· 1 shared Atsushi FushimiiD· 1 shared Britta WeigeltiD· 1 shared Catherine JonesiD· 1 shared Dhivya R. SudhaniD· 1 shared Edaise M. da SilvaiD· 1 shared Elizabeth O’ConnelliD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andrew KoffORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyCancer CellPeer-reviewedOct 10, 2024

Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion

Rei Kudo, Anton Mikhailovich Safonov, Catherine Jones…·Sarat Chandarlapaty

The paper identifies TP53 loss and MDM2 amplification as factors associated with poor long-term response to CDK4/6 inhibition in breast cancer and shows that CDK2 inhibition can overcome this resistance.

72 citationstop 1%

humanbulk RNA-seq

𝕏 PostBluesky